Azala

Tuberculosis Drug Discovery and Development 2019

Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis and still represents one of the global health threats to mankind. The World Health Organization estimated more than 10 million new cases and reported more than 1.5 million deaths in 2019, thus ranking TB among the main c...

Deskribapen osoa

Gorde:
Formatua: Online
Hizkuntza:ingelesa
Argitaratua: MDPI - Multidisciplinary Digital Publishing Institute 2021
Gaiak:
mycobacteria
tuberculosis
multi-drug resistance
drug discovery
promiscuous targets
Mycobacterium tuberculosis
rifampin
isoniazid
mechanisms of resistance
mutations
granulomas
caseum
cell envelope
dormancy
delpazolid
macozinone
DprE1 inhibitor
clinical studies
discovery
mode of action
drug resistance
toxicity
target
energy metabolism
electron transport chain
oxidative phosphorylation
bedaquiline
Q203
MID3
pharmacokinetics
pharmacodynamics
drug-drug interactions
in vitro
in vivo
drug development
tuberculosis treatment
biomarkers
drug combination
clinical trial
BCG
tuberculosis vaccines
TBVI
EDCTP
IAVI
CTVD
host-directed therapy
anti-virulence compounds
TB
post-treatment sequelae
surgery
pulmonary rehabilitation
Carlo Forlanini
artificial pneumothorax
n/a
structure-based drug design
target-based drug design
PknB
PknG
DNA gyrase
antibiotic
mycobacterium
genomics
transcriptomics
proteomics
metabolomics
lipidomics
target identification
mechanism of action
antimicrobial drug resistance (AMR)
target-based screening
phenotypic screening
antituberculosis agents
antimycobacterial
anti-TB drug pipeline
privileged targets
lead generation
thema EDItEUR::G Reference, Information and Interdisciplinary subjects::GP Research and information: general
thema EDItEUR::P Mathematics and Science::PS Biology, life sciences
Sarrera elektronikoa:ONIX_20210501_9783039432363_1078
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Internet

ONIX_20210501_9783039432363_1078

Antzeko izenburuak